Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06962254 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Imatinib and Trametinib for KRAS-mutated Solid Tumor

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
In this pilot trial, participants with unresectable solid cancers harboring KRAS mutations will be provided with a compassionate treatment if their diseases progress after current standard treatments, or there is no available standard treatment. This trial will evaluate the efficacy and safety of the combination of trametinib and imatinib on chemotherapy refractory solid cancers.
Trial Details
NCT Number NCT06962254
Lead Sponsor China Medical University Hospital
Conditions
(from sponsor)		 Solid Tumor Cancer
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov